Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index; 63 of the 117 sources its claims cite were checked for support.

Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies

Open access

Abstract

Platinum-based cancer therapy remains a cornerstone of first-line treatment for several solid tumours such as ovarian, testicular, and non-small cell lung cancers, where it has received regulatory approval as both monotherapy and combination regimens. However, the inevitable emergence of resistance has necessitated extensive preclinical and clinical efforts to develop rational platinum-based combinations. The most appealing candidates for combination therapy are those that offer additive and/or synergistic effects without undesirable overlapping toxicities. Whilst early strategies focussed on co-administration with cytotoxic chemotherapies, recent advances have shifted towards combinations with targeted therapies and immunotherapies, offering improved efficacy and durability of response. In this review, we provide a comprehensive analysis of recent clinical trials evaluating platinum-based combination strategies (excluding radiotherapy) and give an overview of trial concepts that will lead to more refined therapies for cancer. We also highlight emerging dual-drug codelivery nanosystems, platinum-based antibody-drug conjugates (ADCs), and multi-targeted platinum compounds with promising preclinical and/or clinical evidence. Beyond traditional drug pairings, the improved design strategies of new platinum compounds such as their incorporation into ADCs offer enhanced targeting and reactivity. Whilst promising preclinical examples like trastuzumab-Pt(II) and cetuximab-C8Pt(IV) bring optimism to combinatorial approaches, significant challenges including stability and controlled payload release remain to be addressed before clinical translation. By integrating advances in molecular profiling and rational drug development, platinum-based therapies continue to evolve, offering renewed optimism for overcoming drug resistance and improving patient outcomes, although challenges such as biomarker identification, toxicity management, and treatment costs remain to be fully addressed.

Overview

CoChat Summary

TL;DR

This review summarizes recent clinical and preclinical strategies to overcome platinum resistance by combining platinum drugs with cytotoxic agents, targeted therapies, immunotherapies, and emerging delivery/design platforms. It argues that the most promising gains come from rational combinations that preserve or improve efficacy while avoiding overlapping toxicity, with biomarker-guided patient selection increasingly emphasized.

Key findings

  • The review states that current and completed trials examined platinum drugs with cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%).
  • In ovarian cancer, carboplatin/paclitaxel remains a standard backbone, with phase III trials reporting mPFS of 16.8–20.7 months and mOS up to 57.4 months; carboplatin/PLD improved mPFS to 11.3 vs. 9.4 months over carboplatin/paclitaxel in partially platinum-sensitive disease.
  • For platinum-resistant biology, the paper notes ~85% of ovarian cancer patients eventually develop resistance after an initial response, with low response rates to further chemotherapy (<15%), PFS of 3–4 months, and median survival of less than 1 year.
  • Several combinations showed clinically meaningful activity: adavosertib plus carboplatin/paclitaxel improved mPFS to 7.9 vs. 7.3 months; veliparib plus cisplatin/etoposide improved mOS to 10.2 vs. 8.9 months; pembrolizumab plus cisplatin/gemcitabine improved mOS to 12.7 vs. 10.9 months; DCVAC/OvCa plus carboplatin/gemcitabine improved mOS to 35.5 vs. 22.1 months.

Methods

  • Narrative review of platinum-based combination strategies, focusing on recent clinical studies, “the majority of which have been completed since 2019,” and excluding radiotherapy.
  • The paper compiles data across cancer types from clinical trials and selected preclinical studies; it reports the clinical data in Supplementary Table S1.
  • Main analysis is qualitative/comparative: it groups combinations into cytotoxic, targeted, immunotherapy, and other emerging strategies, and compares efficacy, tolerability, and resistance-related rationale.

Limitations

  • The paper states that many combinations still face overlapping toxicity, resistance, biomarker uncertainty, and cost challenges.
  • It also notes that several promising strategies remain preclinical or have not yet entered clinical trials, including platinum-based ADCs and multi-targeted platinum compounds.
  • Evident from the text: this is a review rather than an original trial, so conclusions depend on heterogeneous studies with varying cancer types, regimens, endpoints, and patient selection criteria.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s12032-025-02812-3

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Clinical and FDA-approved anti-cancer platinum-based metallodrugs
Fig. 1 Clinical and FDA-approved anti-cancer platinum-based metallodrugsCC BY · PubMed Central
Fig. 2 Combination strategies of platinum-based drugs (cisplatin or carboplatin) with various therapies have been explored extensively, with cytotoxic agents accounting for 37% of combinations, targeted therapies representing 44%, and immunotherapies comprising 18%. These approaches aim to enhance the therapeutic efficacy of platinum-based chemotherapy by leveraging different mechanisms of action. Cytotoxic agents, such as taxanes and antimetabolites, amplify DNA damage and impair tumour cell repair processes. Targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies (mAbs), selectively enhance the vulnerability of cancer cells to platinum drugs. Immunotherapies, particularly immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4, further potentiate the anti-cancer response by modulating the tumour microenvironment
Fig. 2 Combination strategies of platinum-based drugs (cisplatin or carboplatin) with various therapies have been explored extensively, with cytotoxic agents accounting for 37% of combinations, targeted therapies representing 44%, and immunotherapies comprising 18%. These approaches aim to enhance the therapeutic efficacy of platinum-based chemotherapy by leveraging different mechanisms of action. Cytotoxic agents, such as taxanes and antimetabolites, amplify DNA damage and impair tumour cell repair processes. Targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies (mAbs), selectively enhance the vulnerability of cancer cells to platinum drugs. Immunotherapies, particularly immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4, further potentiate the anti-cancer response by modulating the tumour microenvironmentCC BY · PubMed Central
Fig. 3 Targets for combinations with platinum-based chemotherapy. This figure illustrates key pathways that influence the response to DNA damage and are targeted in combination with platinum-based chemotherapy. These include DNA damage response (DDR) pathways such as homologous recombination (HR) and non-homologous end joining (NHEJ), which are targeted by PARP and ATM/ATR inhibitors. Additionally, cell cycle regulators such as CDK inhibitors play crucial roles in sensitising tumours to platinum therapy. Immune-related mechanisms, including checkpoint inhibitors targeting PD-1/PD-L1, enhance anti-tumour immune responses in combination with platinum drugs and overcome resistance mechanisms
Fig. 3 Targets for combinations with platinum-based chemotherapy. This figure illustrates key pathways that influence the response to DNA damage and are targeted in combination with platinum-based chemotherapy. These include DNA damage response (DDR) pathways such as homologous recombination (HR) and non-homologous end joining (NHEJ), which are targeted by PARP and ATM/ATR inhibitors. Additionally, cell cycle regulators such as CDK inhibitors play crucial roles in sensitising tumours to platinum therapy. Immune-related mechanisms, including checkpoint inhibitors targeting PD-1/PD-L1, enhance anti-tumour immune responses in combination with platinum drugs and overcome resistance mechanismsCC BY · PubMed Central
Fig. 4 Platinum-based antibody–drug conjugate (ADC) as new strategies for specific tumour-targeting. a Platinum compounds are conjugated with monoclonal antibodies (mAbs) to enhance drug delivery and targeting. b Structure of trastuzumab-Pt(II) conjugate. c Structure of cetuximab-C8Pt(IV)
Fig. 4 Platinum-based antibody–drug conjugate (ADC) as new strategies for specific tumour-targeting. a Platinum compounds are conjugated with monoclonal antibodies (mAbs) to enhance drug delivery and targeting. b Structure of trastuzumab-Pt(II) conjugate. c Structure of cetuximab-C8Pt(IV)CC BY · PubMed Central
Fig. 5 Platinum-based ADCs as new strategies for specific tumour-targeting. a Platinum compounds are encapsulated in carrier molecules linked to mAbs to enhance drug delivery and targeting. b Schematic illustration of the preparation of an anti-tissue factor (TF) antibody fragment-antigen binding (Fab') conjugated to polymeric micelles containing an active complex of oxaliplatin, (1,2diaminocyclohexane)platinum(II) (DACHPt) (DACHPt/m). Reprinted from [77], Copyright 2015, with permission from Elsevier. Schematic illustration of the method for preparing oxaliplatin (L-OH)-loaded liposomes linked to either (c) whole cetuximab (CTX) or (d) CTX-Fab’ fragments to their surface. Reprinted from [78], Copyright 2015, with permission from Elsevier
Fig. 5 Platinum-based ADCs as new strategies for specific tumour-targeting. a Platinum compounds are encapsulated in carrier molecules linked to mAbs to enhance drug delivery and targeting. b Schematic illustration of the preparation of an anti-tissue factor (TF) antibody fragment-antigen binding (Fab') conjugated to polymeric micelles containing an active complex of oxaliplatin, (1,2diaminocyclohexane)platinum(II) (DACHPt) (DACHPt/m). Reprinted from [77], Copyright 2015, with permission from Elsevier. Schematic illustration of the method for preparing oxaliplatin (L-OH)-loaded liposomes linked to either (c) whole cetuximab (CTX) or (d) CTX-Fab’ fragments to their surface. Reprinted from [78], Copyright 2015, with permission from ElsevierCC BY · PubMed Central
Fig. 6 Structures of investigational multi-targeted platinum compounds
Fig. 6 Structures of investigational multi-targeted platinum compoundsCC BY · PubMed Central

Verification

Claims the paper makes

56 Valid · 1 Not valid · 42 Not checked · 16 Own results and interpretations

50 more claims · 21 with their cited sources checked

Create a free account to see all 115 claims and to verify the 13 references still open.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Citations

Cites

Show all 166 references

Cited by

See all 40

Metadata

Authors
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R.
Affiliations
  • Sichuan University (CN)
  • Universiti Putra Malaysia (MY)
  • University of Oxford (GB)
  • Swansea University (GB)
Corresponding author
Gill, Martin R.
Venue
Medical Oncology
Published
2025-06-16
Volume
42
Issue
7
Pages
262-262
ISSN
  • 1357-0560 (ISSN-L)
  • 1559-131X
OpenAlex
W4411321113
Cited by
40
References
166
Citations by year
2026: 32 · 2025: 8
FWCI
4.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Medical Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia) (acceptedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
platinum-based chemotherapy, platinum resistance, combination therapy, targeted therapy, immunotherapy, antibody-drug conjugates, drug stability, biomarkers, toxicity management, ovarian cancer, non-small cell lung cancer, testicular cancer
MeSH terms
Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasms, Organoplatinum Compounds, Platinum Compounds, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies. https://app.cochat.ai/papers/10.1007/s12032-025-02812-3
The paper
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025). Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies. Medical Oncology. https://doi.org/10.1007/s12032-025-02812-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.